• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Chinese Pharmaceutical Enterprises Listed on the Global 2000 of Forbes

en-cphi.cnJune 09, 2017

Tag: china , Forbes

Forbes has published the 2017 Global 2000 recently with the ranking based on a composite score from equally-weighted measures of revenue, profits, assets and market value.

The enterprises listed on the "Global 2000" this year are from 58 countries and regions, with total revenue of USD 35.3 trillion, profits of USD 2.5 trillion, assets of USD 169.1 trillion and market value of USD 48.8 trillion. The Industrial and Commercial Bank of China tops the list with annual revenue of USD 151.4 billion and market value of USD 3.4732 trillion.

Regarding the pharmaceutical industry, there are 63 companies listed, with total revenue of USD 1.4 trillion, profits of USD 139.7 billion, assets of USD 2.2 trillion, and total market value of USD 3.3 trillion.

J & J is still the top, with annual sales of USD 71.9 billion and market value of USD 338.6 billion, followed by Pfizer, Novartis, Roche, Sanofi, Bayer and Merck & Co, all among the top 100.

There are 6 Chinese pharmaceutical enterprises listed this year. Sinopharm Group ranks 581st with annual sales of USD 38.9 billion, and CR Pharmaceutical ranks 1029th with annual sales of USD 20.2 billion. Kangmei Pharmaceutical of which the market value has just exceeded RMB 100 billion lately surpasses Hengrui this time, ranking 1487th, and Hengrui ranks 1497th with market value of USD 18.7 billion and is the enterprise with the highest market value among the 6 Chinese pharmaceutical enterprises listed this time.

No.

Ranking

Company

Total revenue in 2016

(USD 100 million)

Profit in 2016

(USD 100 million)

Total assets

(USD 100 million)

Market value

(USD 100 million)

1

32

J & J

719

164

1412

3386

2

47

Pfizer

528

71

1716

2031

3

61

Novartis

485

67

1304

1932

4

79

Roche

513

97

756

2193

5

88

Sanofi

374

52

1104

1161

6

89

Bayer

518

50

901

944

7

100

Merck & Co

396

39

954

1733

8

131

Amgen

227

77

776

1203

9

134

Gilead

303

135

570

870

10

143

AbbVie

256

59

661

1045

11

149

Allergan

146

72

1290

801

12

176

AstraZeneca

230

37

625

752

13

188

McKesson

1965

20

579

305

14

194

GSK

376

12

730

998

15

221

Lilly

212

27

388

941

16

234

BMS

194

45

337

880

17

242

Abbott

209

14

550

757

18

281

Cardinal Health

1272

14

350

260

19

288

Merck

166

18

411

491

20

315

AmerisourceBergen

1483

13

339

190

21

346

Celgene

110

20

281

977

22

348

Takeda

159

12

355

369

23

372

Biogen

105

37

229

580

24

375

Novo Nordisk

166

56

138

882

25

485

Teva

219

3.37

929

324

26

520

Baxter

102

49

155

286

27

528

Astellas

121

19

159

280

28

562

Shire

116

3.42

670

513

29

578

Otsuka Pharmaceutical

110

8.52

227

251

30

581

Sinopharm Group

389

7.01

227

127

31

639

Mylan

111

4.8

347

212

32

806

CSL

64

13

81

439

33

839

Daiichi-Sankyo

89

5.5

170

155

34

986

Regeneron

49

8.8

70

404

35

1023

Sun Pharmaceutical

46

11

91

249

36

1029

CR Pharmaceutical

202

3.64

173

73

37

1047

Zoetis

49

8.21

76

258

38

1076

Quintiles IMS

69

1.15

212

187

39

1144

Actelion

25

7.07

21

305

40

1191

Grifols

45

6.03

107

168

41

1212

UCB

46

6.01

108

146

42

1219

Shionogi

31

8.52

55

174

43

1235

Aleck pharmaceutical

30

3.94

133

260

44

1248

Valeant

97

-24

435

33

45

1299

Medipal Holdings

282

2.96

135

37

46

1304

Eisai

49

5.07

89

149

47

1327

Illumina

24

4.64

43

252

48

1381

Alfresa Holdings

235

3.06

113

40

49

1428

Perrigo

56

-15

175

99

50

1487

Kangmei Pharmaceutical

32

4.96

79

134

51

1497

Hengrui Medicine

16

3.9

21

187

52

1548

Yunnan Baiyao

34

4.57

34

131

53

1584

Suzuken

201

2.44

106

32

54

1591

Novozymes

21

4.53

28

122

55

1594

ONO

22

4.44

106

32

56

1644

Vertex

17

-1.12

29

288

57

1645

Incyte

11

1.04

16

286

58

1716

Lupin

25

4.44

36

99

59

1766

Fosun Pharmaceutical

22

4.23

63

98

60

1901

Jazz

15

3.89

48

92

61

1901

Toho Holdings

118

1.99

56

16

62

1930

BMRN

11

-6.42

40

152

63

1962

Shanghai RAAS

3.26

2.31

20

145

 

Previous:ICH flooded the screen, China’s joining of ICH not officially recognized yet

Next:FDA requests removal of certain prescription opioid for risks related to abuse

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Chinese Pharmaceutical Enterprises Listed on the Global 2000 of Forbes | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Vitamin D2 USP USP Food Additive made in china

Vitamin D2 USP USP Food Additive made in china
Product Registration in China

Product Registration in China

Echinacea Purpurea Extract

Echinacea Purpurea Extract
Cytisine ≥99.0% supplier API Plant extract Pharmaceutical made in china

Cytisine ≥99.0% supplier API Plant extract Pharmaceutical made in china
High quality Cyclobutylmethanamine supplier in China

High quality Cyclobutylmethanamine supplier in China
China Factory Supply 99% Purity Thymosin Beta 4 Thymosin β4 Powder CAS: 77591-33-4

China Factory Supply 99% Purity Thymosin Beta 4 Thymosin β4 Powder CAS: 77591-33-4
Lamivudine USP Pharmaceutical Pharmaceutical API Antiviral drugs Nucleoside made in china

Lamivudine USP Pharmaceutical Pharmaceutical API Antiviral drugs Nucleoside made in china
Hydroxocobalamin EP API Vitamins made in china

Hydroxocobalamin EP API Vitamins made in china
Norethisteron acetate≥98.0% USP API Hormone made in china

Norethisteron acetate≥98.0% USP API Hormone made in china
Fosinopril 98.0%min Pharmaceutical Anti hypertensive drugs Cardiovascular drugs made in china

Fosinopril 98.0%min Pharmaceutical Anti hypertensive drugs Cardiovascular drugs made in china

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service